TWI875895B - 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法 - Google Patents

用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法 Download PDF

Info

Publication number
TWI875895B
TWI875895B TW109144568A TW109144568A TWI875895B TW I875895 B TWI875895 B TW I875895B TW 109144568 A TW109144568 A TW 109144568A TW 109144568 A TW109144568 A TW 109144568A TW I875895 B TWI875895 B TW I875895B
Authority
TW
Taiwan
Prior art keywords
weeks
atrasentan
subject
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW109144568A
Other languages
English (en)
Chinese (zh)
Other versions
TW202130350A (zh
Inventor
菲利浦 Ｔ 弗洛里奇
安德魯 Ｊ 金
奇丹巴拉姆 拉馬強德瑞
莎拉 Ｂ 諾恩伯格
Original Assignee
美商奇努克醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商奇努克醫療股份有限公司 filed Critical 美商奇努克醫療股份有限公司
Publication of TW202130350A publication Critical patent/TW202130350A/zh
Application granted granted Critical
Publication of TWI875895B publication Critical patent/TWI875895B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
TW109144568A 2019-12-17 2020-12-16 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法 TWI875895B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14

Publications (2)

Publication Number Publication Date
TW202130350A TW202130350A (zh) 2021-08-16
TWI875895B true TWI875895B (zh) 2025-03-11

Family

ID=76478538

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109144568A TWI875895B (zh) 2019-12-17 2020-12-16 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法

Country Status (13)

Country Link
US (11) US20210353593A1 (enExample)
EP (1) EP4076652B1 (enExample)
JP (2) JP7624995B2 (enExample)
KR (1) KR20230015874A (enExample)
CN (3) CN116327758A (enExample)
AU (1) AU2020404984A1 (enExample)
BR (1) BR112022012075A2 (enExample)
CA (1) CA3161516A1 (enExample)
IL (1) IL293921A (enExample)
MX (1) MX2022007471A (enExample)
PH (1) PH12022551456A1 (enExample)
TW (1) TWI875895B (enExample)
WO (1) WO2021126977A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
CA3252232A1 (en) * 2022-05-19 2023-11-23 Chinook Therapeutics, Inc. METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
IL320469A (en) * 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody
AU2023378052A1 (en) 2022-11-07 2025-05-29 Chinook Therapeutics, Inc. Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015701A1 (en) * 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury
US20190262317A1 (en) * 2016-10-13 2019-08-29 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
TW202216787A (zh) * 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
MXPA04009234A (es) 2002-03-22 2005-01-25 Kissei Pharmaceutical Agente preventivo o terapeutico para enfermedades renales.
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JP2008513481A (ja) 2004-09-17 2008-05-01 アボット・ラボラトリーズ アトラセンタン塩酸塩の結晶形２
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
MX2008012276A (es) * 2006-03-27 2008-10-08 Genentech Inc Metodos para el tratamiento de alteraciones del riñon.
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2667364A1 (en) 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
EP2413930A4 (en) 2009-03-31 2012-09-26 Ligand Pharm Inc ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
WO2012014663A1 (ja) 2010-07-28 2012-02-02 日本電気硝子株式会社 蛍光体封入用毛細管の製造方法、蛍光体封入用毛細管、波長変換部材及び波長変換部材の製造方法
AU2014259961A1 (en) 2013-04-30 2015-11-05 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
SG11201600107RA (en) 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
UA127339C2 (uk) 2016-01-05 2023-07-26 Юніверсіті Оф Лестер СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA51203A (fr) 2017-11-30 2020-10-07 Idorsia Pharmaceuticals Ltd Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) * 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015701A1 (en) * 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury
TW202216787A (zh) * 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
US20190262317A1 (en) * 2016-10-13 2019-08-29 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Also Published As

Publication number Publication date
KR20230015874A (ko) 2023-01-31
CN116173014A (zh) 2023-05-30
JP2023507739A (ja) 2023-02-27
WO2021126977A1 (en) 2021-06-24
US20210353593A1 (en) 2021-11-18
US20230129646A1 (en) 2023-04-27
US11998526B2 (en) 2024-06-04
CN113272013A (zh) 2021-08-17
WO2021126977A9 (en) 2021-07-22
US20220288027A1 (en) 2022-09-15
US20240108599A1 (en) 2024-04-04
JP2025060686A (ja) 2025-04-10
US12370174B2 (en) 2025-07-29
IL293921A (en) 2022-08-01
US20220288026A1 (en) 2022-09-15
TW202130350A (zh) 2021-08-16
EP4076652A1 (en) 2022-10-26
US20230355580A1 (en) 2023-11-09
US20220304978A1 (en) 2022-09-29
EP4076652A4 (en) 2024-01-03
CA3161516A1 (en) 2021-06-24
MX2022007471A (es) 2022-08-17
US20230364055A1 (en) 2023-11-16
US20250281454A1 (en) 2025-09-11
AU2020404984A1 (en) 2022-07-14
BR112022012075A2 (pt) 2022-08-30
US11491137B2 (en) 2022-11-08
JP7624995B2 (ja) 2025-01-31
US20250120945A1 (en) 2025-04-17
EP4076652B1 (en) 2025-12-03
US20230355579A1 (en) 2023-11-09
PH12022551456A1 (en) 2023-10-23
US12121509B2 (en) 2024-10-22
CN116327758A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
TWI875895B (zh) 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法
US20220304979A1 (en) Methods of reducing disease flares
WO2022148403A1 (zh) 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途
CN105579100A (zh) 多发性骨髓瘤的治疗
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
US20230226041A1 (en) Compounds for the treatment of viral infections
KR20250013180A (ko) 아트라센탄에 의한 국소 분절 사구체경화증의 치료 방법
WO2023222332A1 (en) Diphenyl ureas for the treatment of viral infections
US20230301991A1 (en) Compounds for the treatment of viral infections
JP2023102995A (ja) 慢性腎臓病の治療剤及びそのスクリーニング方法